Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Genzyme Updates Cerezyme Supply; Responds to Sanofi Bid
- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
Clinical Trials News- Clinilabs Selected for a Phase I/II Study of HIV Vaccine
- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
Blogroll
-
Meta
Tag Archives: podcast
Pharm Exec Podcast Series:
Bill Trombetta Industry Audit (Part 2)
[display_podcast]
Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special.
Eli Lilly: With double-digit growth in sales, and a solid improvement in revenue per employee, Lilly placed fourth in the Company of the Year rundown. Bill Trombetta explains Lilly’s position as a big/small pharma and [...]
Pharm Exec Podcast Series:
Bill Trombetta Industry Audit (Part 1)
[display_podcast]
What’s the best managed pharma? Each year, Professor Bill Trombetta of Saint Joseph’s University attempts to answer the question in Pharm Exec’s “Industry Auditâ€, applying a battery of traditional and nontraditional metrics to the largest publicly held companies.
This year, in addition to his article, Bill agreed to sit down with editor-in-chief Patrick Clinton for a [...]

Pharma Unplugged #2 Layoffs & Bonuses